Stay updated on Idasanutlin Combo in AML: Clinical Trial
Sign up to get notified when there's something new on the Idasanutlin Combo in AML: Clinical Trial page.

Latest updates to the Idasanutlin Combo in AML: Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2. This is a minor, non-functional update that does not alter the study details or how users interact with the page.SummaryDifference0.0%

- Check11 days agoChange DetectedPublications section now states that entries are auto-filled from PubMed. The revision tag has been updated to v3.3.1, replacing the previous v3.2.0 wording.SummaryDifference0.1%

- Check18 days agoChange DetectedThe government funding status notice was removed from the page, while the study details, including the title, eligibility criteria, endpoints, and locations, remain unchanged.SummaryDifference0.2%

- Check33 days agoChange DetectedNo significant changes to core study content were observed; any differences appear limited to minor layout or metadata updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference1%

- Check69 days agoChange DetectedAdded revision label v3.1.0 and removed several drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) as well as the earlier v3.0.2 deletion, indicating a shift in content focus and an updated versioning.SummaryDifference0.2%

Stay in the know with updates to Idasanutlin Combo in AML: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idasanutlin Combo in AML: Clinical Trial page.